EGFR and lung cancer: These results suggest that reduced phosphorylation of EGFR might induce the inhibition of downstream signaling molecules in both MAPK/ERK and PI3K-AKT pathways in H1993-MTA cells, and that the signaling pathway alteration caused by the increase of FGF2 might differ according to the molecular features of each lung cancer cell line.